DaVita jumps 10% as AI strategy’s healthcare pick rides stronger guidance

DaVita, a healthcare company, has experienced a remarkable 10% surge in its stock price following stronger-than-expected guidance for the year 2026. The company's earnings guidance of $14.10 to $15.20 per share surpassed the consensus estimate of $14.57 per share, indicating a favorable outlook for investors. This positive development has caught the attention of Investing.com's AI-powered Strategies models, which had already identified DaVita as a strong performer within the Healthcare Heroes strategy.

The stock's price has climbed from $189.32 to $193.86, marking a 10.06% increase since the beginning of the month. With a market capitalization of $12.41 billion, DaVita's valuation is considered attractive by analysts, who assign a Moderate Buy rating and estimate a potential 23% upside from the current price.